Artikel ; Online: Use of insulin glargine during pregnancy: A review.
2021 Band 15, Heft 1, Seite(n) 379–384
Abstract: Backgound and aims: Hyperglycemia during pregnancy is increasing globally. Insulin therapy is considered the standard of care for its optimum management. Insulin glargine, in spite of widespread use in non-pregnant adults, lacks randomized controlled ... ...
| Abstract | Backgound and aims: Hyperglycemia during pregnancy is increasing globally. Insulin therapy is considered the standard of care for its optimum management. Insulin glargine, in spite of widespread use in non-pregnant adults, lacks randomized controlled trial evidence as safe basal insulin during pregnancy. Aim of this review is to discuss major available evidences and recommendations on the use of insulin glargine during pregnancy. Methods: Evidences related to use of insulin glargine during pregnancy, including animal studies, placental transfer studies, case reports as well as observational studies were retrieved using PUBMED & Google scholar. Recommendations regarding use of insulin glargine during pregnancy by international and Indian organizations were reviewed. Results: Trans-placental transfer studies show that insulin glargine does not cross placenta when used at therapeutic concentrations. Although there are no randomized controlled trials on insulin glargine in pregnancy, it's use during pregnancy is not associated with any adverse maternal or neonatal outcomes as shown in many case reports and observational studies (both prospective and retrospective). It's use during pregnancy is hence considered safe by many organizations across the globe. Conclusions: Insulin glargine can be continued safely during pregnancy in women who are already taking it prior to pregnancy and have achieved good glycemic control with it. However we require preferably randomized controlled trials or large prospective observational studies to establish it as first line or preferred basal insulin for management of hyperglycemia during pregnancy. |
|---|---|
| Mesh-Begriff(e) | Animals ; Female ; Humans ; Hypoglycemic Agents/administration & dosage ; Insulin Glargine/administration & dosage ; Insulin, Long-Acting/administration & dosage ; Observational Studies as Topic ; Pregnancy ; Pregnancy in Diabetics/blood ; Pregnancy in Diabetics/diagnosis ; Pregnancy in Diabetics/drug therapy ; Retrospective Studies |
| Chemische Substanzen | Hypoglycemic Agents ; Insulin, Long-Acting ; Insulin Glargine (2ZM8CX04RZ) |
| Sprache | Englisch |
| Erscheinungsdatum | 2021-01-22 |
| Erscheinungsland | Netherlands |
| Dokumenttyp | Case Reports ; Journal Article ; Review |
| ZDB-ID | 2273766-2 |
| ISSN | 1878-0334 ; 1871-4021 |
| ISSN (online) | 1878-0334 |
| ISSN | 1871-4021 |
| DOI | 10.1016/j.dsx.2021.01.012 |
| Datenquelle | MEDical Literature Analysis and Retrieval System OnLINE |
Volltext online
Zusatzmaterialien
Kategorien
Über subito bestellen
Dieser Service ist kostenpflichtig (siehe Lieferbedingungen von subito). Bestellungen, die einen Artikel nebst Supplementary Material umfassen, werden grundsätzlich wie mehrfache Bestellungen bearbeitet. Gebühren fallen in diesen Fällen für jede einzelne Bestellung an.